RecruitingDepression
ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression
Eligible age
18–60 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.
Sponsor: Stanford University
You may qualify if…
- ✓ In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- ✓ 1. Provision of signed and dated informed consent form
- ✓ 2. Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3) and availability for the duration of the study
- ✓ 3. Male or female
- ✓ 4. Age 18-60 years
- ✓ 5. Fluent and literate in English
- ✓ 6. Meets DSM-5-TR diagnostic criteria for MDE (major depressive episode), and criteria for current or recurrent nonpsychotic MDD using the Mini International Neuropsychiatric Interview (MINI Plus)79
- ✓ 7. A total score of 10 or higher on the PHQ-8 at initial screening, including:
You may not qualify if…
- ✕ An individual who meets any of the following criteria will be excluded from participation in this study:
- ✕ 1. Presence of one or more of the following conditions established via the participant's medical record and confirmed using the MINI Plus:
- ✕ bipolar disorder (I, II, not otherwise specified, current or lifetime)
- ✕ psychosis (current or lifetime)
- ✕ moderate to severe alcohol or substance use disorders (current)
- ✕ post-traumatic stress disorder (PTSD; current)
- ✕ obsessive compulsive disorder (OCD; current or lifetime)
- ✕ attention deficit hyperactivity disorder (ADHD; current or lifetime)
Where it's recruiting
California
Palo Alto
Illinois
Chicago
Source: ClinicalTrials.gov · NCT06408246 · last updated 2026-03-05